^
    3d
    Postoperative Radiotherapy Combined With Nimotuzumab Followed by Bemcentinib in High-Risk Patients With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=370, Not yet recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    cisplatin • bemcentinib (BGB324) • TheraCIM (nimotuzumab)
    5d
    Next-generation AI-assisted drug design against cancer: large language models meet conventional in silico methods. (PubMed, In Silico Pharmacol)
    AIC1 showed the highest binding affinity (- 10.079 kcal/mol), surpassing clinical-stage bemcentinib (- 8.234 kcal/mol)...This work pioneers LLM-driven in silico design of AXL inhibitors, offering a scalable blueprint for accelerated anticancer drug development. The online version contains supplementary material available at 10.1007/s40203-026-00582-y.
    Journal
    |
    GAS6 (Growth arrest specific 6)
    |
    bemcentinib (BGB324)
    10d
    KEYNOTE-D35: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=120, Active, not recruiting, Qurient Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Mar 2028 | Trial primary completion date: Oct 2025 --> Dec 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • adrixetinib (Q702)
    14d
    Super-Enhancer-Driven SOX4/SMAD3 Mediate Membrane Remodeling by Regulating Phospholipid Metabolism to Accelerate Leukemia Progression. (PubMed, Adv Sci (Weinh))
    Notably, the AXL inhibitor Bemcentinib effectively suppressed CML-BP progression in both in vivo and in vitro models. Collectively, our findings establish SE-driven SOX4 and SMAD3 as key regulators in CML-BP and identify Bemcentinib as a promising therapeutic strategy.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • LPCAT1 (Lysophosphatidylcholine Acyltransferase 1) • SMAD3 (SMAD Family Member 3) • SOX4 (SRY-Box Transcription Factor 4)
    |
    bemcentinib (BGB324)
    17d
    QRNT-012: Study of Q702 in Subjects with Relapsed or Refractory Chronic Graft-versus-Host Disease (cGVHD) (2025-522680-14-00)
    P1, N=16, Recruiting, Qurient Co. Ltd.
    New P1 trial
    |
    adrixetinib (Q702)
    1m
    ARC-27: A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (clinicaltrials.gov)
    P1, N=91, Active, not recruiting, Arcus Biosciences, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    EGFR mutation • ALK mutation • MET mutation
    |
    docetaxel
    1m
    A Multikinase Inhibitor AX-0085 Blocks FGFR1 Activation to Overcomes Osimertinib Resistance in Non-Small Cell Lung Cancer. (PubMed, Biomedicines)
    Additionally, AX-0085 inhibited AXL and FGFR1-dependent oncogenic events, including cell proliferation, clonogenicity, and migration. The dual inhibition of AXL and FGFR1 by AX-0085 can overcome acquired osimertinib resistance, supporting its potential as a therapeutic strategy for treating patients with osimertinib-resistant tumors.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • FGFR1 (Fibroblast growth factor receptor 1)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • AX-0085 • simmitinib (SYHA1817)
    2ms
    Cerebraca-02/3: Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma (clinicaltrials.gov)
    P2/3, N=175, Not yet recruiting, Everfront Biotech Co., Ltd.
    New P2/3 trial
    |
    temozolomide
    2ms
    Structural Analysis of Tilvestamab in Complex with AXL. (PubMed, ACS Omega)
    Both SAXS and cryo-EM confirmed successful complex formation between the three proteins, and a low-resolution 3D model for the tilvestamab-AXL complex is presented. The data allow for sample optimization for high-resolution structural biology, as well as designing mutations that could alter binding affinity and specificity.
    Journal
    |
    AXL (AXL Receptor Tyrosine Kinase) • GAS6 (Growth arrest specific 6)
    |
    tilvestamab (BGB149)
    2ms
    A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease (clinicaltrials.gov)
    P1, N=18, Recruiting, Qurient Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    adrixetinib (Q702)
    2ms
    Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=51, Completed, Qurient Co., Ltd. | Active, not recruiting --> Completed | N=78 --> 51 | Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    adrixetinib (Q702)
    3ms
    KEYNOTE-C62: Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers (clinicaltrials.gov)
    P1/2, N=36, Terminated, SignalChem Lifesciences Corporation | N=92 --> 36 | Trial completion date: Sep 2028 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Sep 2026 --> Dec 2025; Lack of efficacy and enrollment challenges
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • SLC-391